Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Effect of allergen-specific immunotherapy with purified Alt a1 on AMP responsiveness, exhaled nitric oxide and exhaled breath condensate pH: a randomized double blind study"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Effect of allergen-specific immunotherapy with purified Alt a1 on AMP responsiveness, exhaled nitric oxide and exhaled breath condensate pH: a randomized double blind study. | Prieto et al. Allergy Asthma Clinical Immunology 2010 6 27 http www.aacijournal.eom content 6 1 27 ALLERGY ASTHMA CLINICAL IMMUNOLOGY RESEARCH Open Access Effect of allergen-specific immunotherapy with purified Alt al on AMP responsiveness exhaled nitric oxide and exhaled breath condensate pH a randomized double blind study 1 2 2 1 1 11 Luis Prieto Ricardo Palacios Dulce Aldana Anna Ferrer Carmen Perez-Frances Victoria Lopez Rocio Rojas Abstract Background Little information is available on the effect of allergen-specific immunotherapy on airway responsiveness and markers in exhaled air. The aims of this study were to assess the safety of immunotherapy with purified natural Alt a1 and its effect on airway responsiveness to direct and indirect bronchoconstrictor agents and markers in exhaled air. Methods This was a randomized double-blind trial. Subjects with allergic rhinitis with or without mild moderate asthma sensitized to A alternata and who also had a positive skin prick test to Alt a1 were randomized to treatment with placebo n 18 or purified natural Alt a1 n 22 subcutaneously for 12 months. Bronchial responsiveness to adenosine 5 -monophosphate AMP and methacholine exhaled nitric oxide ENO exhaled breath condensate EBC pH and serum Alt a1-specific IgG4 antibodies were measured at baseline and after 6 and 12 months of treatment. Local and systemic adverse events were also registered. Results The mean 95 CI allergen-specific IgG4 value for the active treatment group increased from 0.07 pg mL 0.03-0.11 at baseline to 1.21 pg mL 0.69-1.73 P 0.001 at 6 months and to 1.62 pg mL 1.02-2.22 P 0.001 at 12 months of treatment. In the placebo group IgG4 value increased nonsignificantly from 0.09 pg mL 0.06-0.12 at baseline to 0.13 pg mL 0.07-0.18 at 6 months and to 0.11 pg mL 0.07-0.15 at 12 months of treatment. Changes in the active treatment group were significantly higher than in the placebo group both at 6 months P 0.001 and at 12 months of treatment P 0.0001 . .